CRISPRIL
The CRISPRIL consortium was established to address the CRISPR-Cas challenges. The consortium
aims to develop an artificial intelligence-based system, “GOGENOME”, providing users with
improved genome-editing workflows, and predictable accuracy and efficacy.
MAY 2020
Start Date
DECEMBER 2020
First milestone
OCTOBER 2021
Additional funds received
April 2023
End Date
Goals & Objectives
Towards a Safe and Accurate Genome Editing CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a groundbreaking and leading technology in the biotech and health industry in recent years. The ability to generate precise genomic modifications in a relatively simple and efficient manner revolutionized the ability of scientists to study various types of diseases, develop improved crops and livestock and understand genetic processes.
NRGene’s Activity Within the Project
NRGene is the leading company in CRISPR-IL and is contributing bioinformatic editing analysis and AI components to the consortium’s infrastructure. NRGene is managing the consortium’s AWS infrastructure and develops the Go-Genome web platform that would serve as a future CRISPR-IL interface. On the analysis aspect, NRGene is responsible for building the bioinformatic pipeline that measures the editing results. Finally, as part of the consortium’s AI effort, NRGene is developing a unique AI module that predicts the best combination of experimental methods to reach a specific editing result.
